Grossman re-joined Thoratec after taking over at Conceptus in December 2011 and leading it to a $1.1 billion sale to Bayer in June 2013 (he’d been Thoratec’s CEO from 1996-2006). Grossman helmed Thoratec until St. Jude Medical (now Abbott) acquired it in October 2015 for $3.3 billion.
Nevro said the deal with Broadfin also involves the expansion of its board of directors with the addition of Warburg Pincus limited partner Bess Weatherman and medtech veteran Kevin O’Boyle and the departure of director Ali Behbahani. Broadfin picked up a 5.8% stake in Nevro in September 2015 but cut that to less than 0.2% in February 2017, according to regulatory filings.
“On behalf of the board and our entire company, I am excited to welcome Keith Grossman to the Nevro team,” chairman Michael DeMane said in prepared remarks. “Keith brings over 30 years of experience in leading innovative medical technology companies through periods of strategic change to deliver growth and enhanced value for stockholders. As we look to the future, I am confident that under Keith’s direction, Nevro will be well positioned to capture a burgeoning market opportunity with its pioneering spinal cord stimulation (SCS) technology to treat chronic pain.”
“I am excited by this opportunity to join such a talented team at a pivotal moment in Nevro’s history,” Grossman added. “Over the past several years, Nevro has leveraged the strength of its technology to enhance patient care and drive overall industry growth. Nevro is now at an inflection point, and I am confident in our ability to continue delivering value not only to our patients and customers, but importantly, to our stockholders. I look forward to working closely with the board and the full Nevro team to advance the company into its next phase of growth.”
Broadfin also agreed to back Nevro’s board nominees at its next shareholders meeting and to obey standstill provisions and voting commitments. Nevro said it’s suspending its revenue guidance pending Grossman’s assessment.
NVRO shares were up 25.0% to $55.96 apiece today in pre-market trading ahead of a $44.51-per-share open and jumped 33.8% to $59.91 shortly thereafter.
“Ms. Clarke is an incredible addition to our team,” CEO Peter Wehrly said in prepared remarks. “With her accomplished background and experience working for companies at critical inflection points, Ms. Clarke will play a key role at Synaptive as we continue expanding our presence globally.”
“I’m very excited to join Synaptive and work closely with the team to continue advancing their efforts in transforming neurosurgical technologies,” Clarke added. “Given the increasing need for advanced neurological care, I’m pleased to be working for a company that is committed to providing physicians the tools necessary to achieve optimal patient outcomes.”